Brutalist Biotech

• Baxter cuts financial forecast while pausing infusion pump shipments (16h)
• Lepu Biopharma supplies two T-cell engagers to new company in $857M deal (17h)
• Spine BioPharma misses primary endpoint in back pain phase 3, blames sham response rate (17h)
• Sanofi pens $395M China pact for Arrowhead metabolic med awaiting approval decision (20h)
• 4DMT’s stock climbs as eye disease gene therapy patients keep jettisoning injections (22h)
• Allogene reports patient death, discontinues investigational antibody in CAR-T pivotal trial (1d)
• Chutes & Ladders—Novo Nordisk nominates CEO successor (1d)
• Instil's licensed PD-L1xVEGF bispecific shows promise in China, instilling hope for upcoming US test (1d)
• AbbVie’s IL-1 asset misses mark as monotherapy in phase 2 ulcerative colitis study (1d)
• AbbVie's rumored $1B pursuit of Gilgamesh could fit into its growing neuroscience portfolio (1d)

• Regeneron cancer bispecific rejected again; Allogene discloses trial death (16h)
• US to install country-specific tariffs Aug. 7 (2d)
• Trump redoubles threats in attempt to strongarm drugmakers on prices (1d)
• Experts ousted from CDC panel warn of damage to US vaccine policy (1d)
• In rumored AbbVie deal, Wall Street sees momentum for psychedelics MA (1d)
• Alnylam reaches new highs on strong sales of closely watched rare disease drug (1d)
• Venture firm Frazier closes $1.3B fund for early-stage biotech investing (1d)
• Moderna to lay of 10% of workforce in ‘difficult but necessary step’ (1d)
• Lilly’s Mounjaro protects heart health in large diabetic study (1d)
• Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval (2d)

• Eating disorder telehealth startup Equip raises $47M (11h)
• Replimune says it's waiting for FDA on a path forward for rejected cancer treatment (12h)
• CMS considers pilot plan for covering weight loss drugs — report (12h)
• Lilly to sell New Jersey facility as it nears picks for new US sites (14h)
• Moderna gets UK appeals court win in Covid patent battle with Pfizer, BioNTech (14h)
• FDA requires opioid label updates to highlight long-term risks (15h)
• Regeneron CEO speaks on Trump's 'most favored nation' pricing (16h)
• Analysts wary of Moderna's CMV fate after new endpoints added (16h)
• Sanofi buys China rights to Arrowhead’s lipid drug for $130M upfront (17h)
• United Therapeutics' $1B share buyback; Layoffs at a Roivant subsidiary (18h)

• Regulatory Roadblocks Blemish Regeneron’s Otherwise Strong Q2 (16h)
• Moderna Cutting 10% of Workforce Globally (16h)
• Moderna Wins UK Patent Battle Against Pfizer and BioNTech (17h)
• Moderna’s Bancel Nay on M&A, Yay on R&D Partnerships (17h)
• After Prasad’s Ouster, Makary Looks for Better Drug, Biologic Alignment at FDA (18h)
• ‘Very Impressive’ Amvuttra ATTR-CM Sales Send Alnylam Soaring (19h)
• Merck’s $3B Savings Push Claims 6,000 Jobs (19h)
• Trump Asks Big Pharmas to Move on Most Favored Nation Drug Pricing—Or Else (1d)
• FDA Issued Myeloma, Alzheimer’s Approvals in July but Rejected Two CGTs (1d)
• Future of BMS’ Cobenfy Still in Limbo After Phase III Fail (1d)

Bio IT World

• Longitude Prize on ALS Launches, UK Biobank Completes World’s Largest Whole Body Imaging Project, More (2d)
• Follow the Money: Universal Flu Vaccine, Full-Length Single-Molecule Protein Sequencer, More (3d)
• Arab Pangenome Reference Published (4d)
• Multiomics Platform Integration Advances Cancer Treatment Predictions (1w)
• Innovative Practices Award for NHS England, IQVIA Privacy Protection Platform (1w)
• NIST Releases First Cancer Cell Line for Public Genomic Research (2w)
• The New Frontier in Alzheimer’s Prevention: AI-Powered Neurodiagnostic Solutions (2w)
• A Popular Alzheimer’s Biomarker Found at High Levels in Newborns (2w)
• Pharma Companies Finding Their Way with AI (3w)
• Trends from the Trenches: What a TV Scientist Knows About Teaching Science (3w)

• AIDS activists sue HHS to obtain Gilead settlement over patents for HIV prevention pills (12h)
• In health insurers’ race to offload unprofitable members, winners begin to emerge (14h)
• Up and down the ladder: The latest comings and goings (15h)
• FDA to stress opioids’ risk of overdose, death in new medication safety labels (17h)
• Trump demands drugmakers slash U.S. price now (18h)
• We’re reading about Trump demands on drug prices, a 340B pilot program, and much more (18h)
• Childhood vaccination rates fall again, raccoons are not friends, and more health news (18h)
• MAGA influencers take a sudden interest in Medicare Advantage reforms, echoing a dark money group (23h)
• The FDA’s plan on fluoride supplements is bad science (23h)
• The U.S. needs a revolution to harness the potential of GLP-1s for weight loss (23h)

• OpenAI-Backed Ambience Raises $243M in Series C, Reaching $1B+ Valuation (2d)
• AI-Native Formation Bio Licenses Monoclonal Antibody After $372M Raise in 2024 (3d)
• "AI Scientists"—New Collaborators for Rare Disease Research? (4d)
• Modi Ventures Closes $88M Second Fund for AI–Biology Convergence Investments (1w)
• Latent Labs Launches Web-Based AI Tool for Custom Protein Generation (1w)
• UK Rolls Out National Strategy to Build Europe’s Life Sciences Powerhouse by 2030 (2w)
• Japan’s Elix Launches AI Drug Discovery Platform Trained on Confidential Pharma Data via Federated Learning (2w)
• Google Expands MedGemma Collection With Multimodal Health AI Models for Open Development (3w)
• Xaira Therapeutics Appoints Biotech Exec Behind Belharra and Ambys as President and COO to Scale AI-Driven Drug Discovery Platform (3w)
• NIH To End Funding for Animal-Only Studies, Backing Shift to New Approach Methodologies (3w)

• Oncolytic virus therapy for cancer: what’s been going on in 2025? (18h)
• Meatly’s innovative cultivated meat is already delighting pets, are humans next? (23h)
• Targeting orexin: the future of narcolepsy treatments (2d)
• 10 biotech companies leading the way in Denmark (3d)
• How to solve the biotech bottleneck by funding ideas, not data (4d)
• Cryoport Systems on the state of the ATMP market and the importance of supply chain resilience (1w)
• Which biotech companies are gaining traction in genetic diseases? (1w)
• Biotech stars of 2024, did they shine or fade in 2025? (1w)
• Eight biotechs in Belgium making leaps in the clinic (1w)
• NATO Innovation Fund invests in first biotech: what’s to come? (2w)

• Mass Spectrometry for the Masses (16h)
• Top 10 U.S. Biopharma Clusters 2025 (16h)
• Reading the Masterminds of the Human Body (16h)
• Designer Stem Cells Power New R&D Assay Systems (16h)
• Gene Therapy Companies Set Sights on Cardiovascular Disease (16h)
• Epigenetic Editors Make Their Marks in the Clinic (16h)
• Making New Connections: Antibody Drug Conjugates Target Cancer (16h)
• Bringing RNA-Based Therapies Full Circle (16h)
• A Noble Pursuit: Genetics and Drug Discovery Revisited (16h)
• Quantifying the Breakome (16h)

• What Patients With Cancer Need to Know About Bladder Removal Surgery (10h)
• Minimally Invasive Surgery Transforms Lung Cancer Recovery (11h)
• BMT-CARE App Improves Quality of Life and Mental Health for Caregivers (12h)
• Understanding Epithelioid Hemangioendothelioma: A Rare Vascular Cancer (14h)
• How Robotic Surgery Can Impact Outcomes For Those With Lung Cancer (15h)
• Oncolytic Virus Wins FDA Fast Track Designation in Soft Tissue Sarcoma (16h)
• The Significance of the Datroway FDA Approval in EGFR+ NSCLC (18h)
• FDA Grants Orphan Drug Status to SAR446523 for Relapsed Myeloma (1d)
• What is a Neobladder? What Patients with Bladder Cancer Need to Know (1d)
• How Resilience Coaching May Help Young People With Advanced Cancer (1d)

Contract Pharma*

• Everest Medicines Invests $30.9M in I-Mab (18h)
• Velocity Clinical Research Appoints Ines Abs Country Head of Germany (18h)
• Moderna to Cut 10% of Global Workforce (19h)
• Meitheal Pharmaceuticals Expands Medical Affairs Operations with Two Appointments (1d)
• Flow Sciences Announces New Office in North Carolina (1d)
• Symbiosis Completes 1,000th Batch of Injectable Drug Product (1d)
• PL BioScience Announces Major Site Expansion (1d)
• Hoth Therapeutics Engages ICON to Expand Clinical Trial for HT-001 (2d)
• Evotec, Sandoz Announce Potential Sale of Just – Evotec Biologics EU (2d)
• Tobin Scientific Acquires Wakefield Moving & Storage (2d)

• Eisai data shows sustained benefit of lecanemab in early Alzheimer’s disease (1d)
• Moderna wins EU approval for updated COVID-19 vaccine (1d)
• Filgotinib meets phase 3 endpoint in axial spondyloarthritis trial (3d)
• NICE backs AstraZeneca’s dual immunotherapy for advanced liver cancer (3d)
• Exonate to launch phase 2b trial of EXN407 for diabetic eye disease (3d)
• PharmaTimes Clinical Researcher of the Year – The Americas (3d)
• Moderna’s updated COVID-19 vaccine receives positive EMA opinion (4d)
• Akari Therapeutics advances research on novel PH1 payload for targeted cancer therapy (1w)
• Kling Bio partners with Sanofi to accelerate antibody discovery (1w)
• 4TEEN4 begins trial of antibody therapy for cardiogenic shock (1w)

• Sutter Health Says Flosonic’s Wearable Ultrasound Can Save Lives in the ED (8h)
• Evvy Provides Bacterial Vaginosis Symptom Relief, Study Finds (9h)
• MedCity FemFwd: Advancing Value-Based Care in Women’s Health (10h)
• Why Are 21st Century Hospitals Monitoring Kidney Function with 1930s Technology? (17h)
• Communicating with Employees During Times of Turmoil (18h)
• The Future of Healthcare Isn’t Just Smart, It’s Human (18h)
• Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs (1d)
• 3 Notable Health Tech Funding Announcements in July (1d)
• MedCity Pivot Podcast: How the Right Payment Tech Can Foster Better Payer-Provider Relationships (1d)
• Taking an Interdisciplinary Approach to Chronic Disease Management (1d)

• Jennifer Doudna is named 2026 Priestley Medalist (14h)
• Modular reaction can build hundreds of unnatural amino acids (16h)
• NIH director Bhattacharya denies banned word list in meeting with staffers (1d)
• Venepalli receives 2025 Whalen Award (1d)
• This machine is designed to wind (1d)
• Bacteria built with smallest genetic code ever (1d)
• Comment: 50 Years of leadership: Celebrating the ACS public policy fellows (1d)
• Business briefing for July 30 (2d)
• BASF and Dow struggle in the second quarter (2d)
• Amid controversy, industry goes all in on plastics pyrolysis (2d)

The Pharma Letter*

• UK court finds Moderna patent infringed by BioNTech/Pfizer’s Comirnaty (15h)
• Regeneron rises as 2nd-quarter beats forecasts (15h)
• Biogen beats earnings estimate and ups outlook (16h)
• US-EU trade deal puts pharma at substantial fiscal risk, say analysts (17h)
• Moderna declines on mixed 2nd-quarter financials (18h)
• Trump writes to pharma bosses with demands on pricing (19h)
• $1.3 billion raised for Frazier Life Sciences’ latest innovative therapeutics quest (20h)
• Italy approves reimbursement of gene therapy Hemgenix (20h)
• Lilly's Mounjaro demonstrates cardiovascular protection (21h)
• FDA calls for major changes to opioid drug labelling (22h)

• Sustained Benefit in Advanced RCC with Pembrolizumab and Axitinib (12h)
• Frontline Metastatic RCC Therapy Improved With Long-Term Data (13h)
• The Future of Dato-DXd in Lung Cancer and Beyond (14h)
• Rethinking Rectal Cancer End Points: pCR Not a Survival Surrogate (16h)
• July's Oncology Approvals: A Landmark Month for Cancer Treatment Advancements (17h)
• Cabozantinib/Atezolizumab Improves PFS in Patients With mCRPC and Extrapelvic Metastases (18h)
• Advancing Prostate Cancer Treatment With Shared Decision-Making (1d)
• Toxicity Management for Dato-DXd: Stomatitis, Eye Issues, and ILD (1d)
• Novel GPRC5D mAB Receives FDA Orphan Drug Designation in R/R Myeloma (1d)
• Novel Combinations Show Promise in Resectable NSCLC, Led by ADC-Chemo-Immuno Triplet (1d)

• Moderna lays off 10% of staff worldwide (18h)
• Several pharmaceutical companies respond to Trump's price threats (18h)
• Media: Trump administration rumored to include Wegovy and Ozempic in Medicare (20h)
• AbbVie upgrades after better-than-expected second quarter (21h)
• Analysts after Trump letter with price demands: "Nobody knows what's going to happen" (22h)
• Analysts after Trump letter with price demands: "Nobody knows what's going to happen" (23h)
• Novo Nordisk responds to Trump's demands for price reductions (1d)
• AbbVie nears third central nervous system acquisition in two years (1d)
• Several obesity stocks hit after Novo Nordisk dive: "Investors see this as a unified market" (1d)
• Sanofi profit growth slowed by spending on research (2d)

• Vinay Prasad: That Was Fast (2d)
• It All Comes Down to the Mitochondria (3d)
• SSRIs As Cancer Therapy (4d)
• A New Cause of Atherosclerosis (1w)
• The Downsides of Therapies - And What to Do About Them (1w)
• Treating Light-Chain Amyloidosis Is Not Easy Work (2w)
• Sarepta, Sarepta (2w)
• Tell Me Again About Neurons Now (2w)
• Testing the Role of Consciousness (2w)
• Dual Antibody Conjugates For Twice the Excitement (2w)

• NHS broadens access to haemophilia A drug Hemlibra (20h)
• ChatGPT can cut review times for clinical trial eligibility (21h)
• Tech giants back unified health data-sharing platform in US (22h)
• Trump gives pharma ultimatum on most favoured nation pricing (1d)
• Moderna cuts staff amid operating 'uncertainty' (1d)
• Lilly trumpets heart health data with Mounjaro (1d)
• Google wearable AI can 'learn the language of our bodies' (1d)
• Is AbbVie planning an epic Gilgamesh takeover? (1d)
• Tidmarsh to stand in for Prasad's role at CBER (2d)
• NICE CEO to step down by year-end (2d)

• This week in drug discovery (28 July – 1 August) (17h)
• Sanofi’s antibody earns orphan status for multiple myeloma (19h)
• RWD shows shingles vaccine reduces dementia risk (21h)
• Peptide for Alzheimer’s increases clearance of amyloid plaques (23h)
• Boehringer and Re-Vana partner on long-acting ophthalmic therapies (1d)
• AMR will cost $187b more every year without EU investment (1d)
• Elahere gets UK approval in platinum-resistant ovarian cancer (2d)
• MapLight Therapeutics makes $372.5m in series D financing (2d)
• Adaptimmune sells cell therapies to US WorldMeds (2d)
• Roche’s AD study shows rapid clearance of amyloid plaques (3d)

Google News Biotech

• Australia searches for the next CSL - BioSpectrum Asia (2h)
• Resurging Funding Catapults APAC Biotech Startups - BioSpectrum Asia (2h)
• Is Viking Therapeutics the Next Big Biotech Bet? - The Globe and Mail (7h)
• Is Viking Therapeutics the Next Big Biotech Bet? - MSN (8h)
• Whistleblower who said biotech manufacturer defrauded federal agencies settles lawsuit - Rhode Island Current (9h)
• Whistleblower who said biotech manufacturer defrauded federal agencies settles lawsuit - News From The States (9h)
• Whistleblower who said biotech manufacturer defrauded federal agencies settles lawsuit - Yahoo Home (9h)
• Moleculin Biotech Releases Corporate Presentation Update - TipRanks (10h)
• Local biotech co-founder named to Forbes 50 Over 50 - The Business Journals (10h)
• KRYSTAL BIOTECH Earnings Preview: Recent $KRYS Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative (10h)